Signal
Court Invalidates Kaneka Ubiquinol Patent Opening U.S. Market for Cocrystal Technology Alternatives
- Category
- · Ecosystem Shift · Global
- Date
- September 7, 2026
- Source
- OVUM
Summary
The U.S. District Court has overturned Kaneka's '080 patent for lack of utility and enablement. This ruling clears the legal path for Cocrystal Tech to market CrysQnol, a bioavailable ubiquinol alternative, to U.S. supplement manufacturers and consumers.
Positions inside women's health are shifting, and the useful question is which neighbouring companies are affected. Watch for follow-on moves from the investors, incumbents, and new entrants named here.
OVUM interpretation layer
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- OVUM Primary source
The OVUM Intelligence Brief
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.